Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Scinderin (SCIN)
- Target
- SCIN
- Molecular classification
- Actin-binding protein, Actin filament-severing and capping protein, Part of the gelsolin superfamily
01
Overview
Scinderin (SCIN), also known as adseverin, is a calcium-dependent, actin-binding protein that belongs to the gelsolin superfamily. It is primarily responsible for severing, capping, and nucleating actin filaments, modulating the structure and plasticity of the cortical actin network. Highly expressed in secretory tissues, scinderin plays a central role in vesicle trafficking and exocytosis by reorganizing actin to allow secretory vesicle access to the plasma membrane upon calcium signaling. Scinderin is further implicated in cell differentiation, cell maturation, and apoptosis, especially in hematopoietic cells, and has a role in the fusion of muscle stem cells with muscle fibers during repair and regeneration. The protein acts as a molecular switch, severing actin filaments in the presence of calcium and promoting filament assembly when calcium levels normalize. While it is functionally crucial for cell secretion and remodeling, no specific therapeutics currently target scinderin, but it may have relevance in cancer biology, muscle diseases, and platelet disorders.
- Other names
- AdseverinKIAA1905scinderinadseverin
02
Mechanism of action
Not applicable (as above, no drugs currently act directly on scinderin in a therapeutic context)
03
Biological functions
Actin filament severing (calcium-dependent)Actin filament cappingActin nucleationRegulation of exocytosis (vesicle release)Regulation of cortical actin dynamicsCell maturation, differentiation, apoptosis (notably in secretory and hematopoietic cells)
04
Disease associations
Cancer (role in cell differentiation, secretion, and possibly tumorigenesis)Platelet and megakaryocyte disordersMuscle regeneration/fusion and muscle disease (via myogenic cell fusion)Other (general cytoskeletal dysfunction, secretory disorders)
05
Safety considerations
None specific to therapeutic targeting; experimental manipulation might disrupt cell secretion, platelet function, or cytoskeletal regulationThere is no information on direct pharmacological targeting safety or clinical use.
06
Interacting drugs
None documented in current literature. No approved small-molecule or biologic drugs are known to directly target scinderin for clinical use.
07
Biomarkers
Overexpression or induction of scinderin may be used as a biomarker in studies of muscle regeneration (e.g., MuSC fusion) or certain cancers, but there are no established clinical biomarkers for patient selection or therapy monitoring
Beyond the preview
Go deeper on Scinderin (SCIN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scinderin (SCIN).